CTLA4 and neoplasm: However, tumor-infiltrating lymphocytes and the expression of immune markers such as PD1, PDL1, and CTLA4 have recently been found to correlate with pCR in TNBC.36–41 NLR is relatively low in tumor subtypes with high lymphocyte activity, such as TNBC.42–44 Chemotherapy further activates the immune response in patients with low NLR, thereby accelerating the anti-tumor effect.17–19,21,45